Compare Prudential Financial Inc (PRU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs TG Therapeutics Inc — how do they compare? Prudential Financial Inc trades at $117.5 (market cap $41.19B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Prudential Financial Inc is far larger — about 4.8× TG Therapeutics Inc's market cap, and Prudential Financial Inc pays a 4.69% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PRU | TGTX | |
|---|---|---|
Market Cap | $41.19B | $8.53B |
Sector | Financials | Health |
52-Week High | $125.13 | $59.06 |
52-Week Low | $92.00 | $26.94 |
Enterprise Value | $69.96B | $8.74B |
Dividend Yield | 4.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRU trades at $119.38, down 2.16% today, with a neutral technical outlook and mixed earnings history. The stock shows strong profitability with a 6.04% net margin and 12.46% ROE, while valuation metrics like a P/E of 10.82 and P/S of 0.64 appear attractive. Recent news highlights PGIM's ETF launches and conference participation, signaling strategic focus.
The outlook is cautious; analyst consensus is a Hold with a $113.20 target below the current price. Risks include volatile cash flows and high leverage, but steady dividends and earnings beats offer support. Upside depends on execution of cost reductions and capital-light growth amid economic uncertainty.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
